J&J Settles Talc Lawsuits for $5.5 Billion

Johnson & Johnson has reached an agreement to pay $5.5 billion to resolve outstanding lawsuits that link its talc products to ovarian cancer. This proposed settlement aims to conclude a lengthy legal dispute that has persisted for more than ten years.

The company's subsidiary, Red River Talc, had previously proposed a $9 billion settlement, which a U.S. bankruptcy court judge denied last year. Johnson & Johnson opted not to appeal this decision and instead prepared to continue fighting the cases in court.

Recently, a federal judge ordered plaintiffs to demonstrate why the remaining talc claims should not be dismissed, citing a lack of direct evidence linking the product to cancer from expert witnesses. Erik Haas, worldwide vice president of litigation for Johnson & Johnson, stated that the court's order put plaintiffs in a difficult position without necessary evidence.

Under the terms of the new settlement, Johnson & Johnson plans to make an initial payment of no more than $3 billion in 2027. Significant payments are not expected again until 2028. The company expressed confidence in ultimately prevailing in further litigation but sees this resolution as a way to move forward and focus on its core mission of developing life-saving medicines and devices.

Johnson & Johnson previously settled approximately 95% of lawsuits concerning mesothelioma, all state consumer protection claims, and all talc-supplier disputes. Following this news, shares of the New Brunswick, New Jersey-based company saw an increase of over 2% before market open.